Livanova PLC Form 4 insider transactions

Anne M. Liddy, Chief Legal Officer of LivaNova PLC, received 6,291 shares of common stock on September 15, 2026.

Francesco Bianchi, a Director of LivaNova PLC, sold 3,500 shares of common stock on September 10, 2026 for $78.01 per share.

Brooke Story, a Director of LivaNova PLC, sold 2,300 shares of common stock on September 4, 2026 for $81.42 per share.

Francesco Bianchi, a Director of LivaNova PLC, sold 1,650 shares of common stock on August 31, 2026 for $79.72 per share.

Ahmet Tezel, Chief Innovation Officer of LivaNova PLC, sold 2,675 shares of common stock on August 11, 2026 for $77.74 per share.

LivaNova PLC director Peter M. Wilver reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC director Todd C. Schermerhorn reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC director Francesco Bianchi reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC Director Susan M. Podlogar reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC director Barry James Christopher reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC Chief Innovation Officer Ahmet Tezel reports transactions involving ordinary shares and restricted stock units.

Jette Nygaard-Andersen, a Director at LivaNova PLC, was granted 2,383 Restricted Stock Units (RSUs) under the 2025 Director Incentive Award Plan.

LivaNova PLC director William A. Kozy reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC director Stacy Enxing reported transactions involving ordinary shares and restricted stock units, including acquisitions and disposals related to tax obligations and vesting schedules.

LivaNova PLC director Brooke Story reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC director Donald Zurbay reported transactions involving ordinary shares and restricted stock units on June 15, 2026.

LivaNova PLC Director Francesco Bianchi sold 1,800 ordinary shares at a price of $75.75 per share.

LivaNova's Chief Innovation Officer, Ahmet Tezel, reported the vesting of restricted stock units and new grants of both restricted and performance stock units.

LivaNova PLC's President of Cardiopulmonary, Franco Poletti, reported routine share transactions related to RSU vesting and tax obligations.

LivaNova PLC's Chief Financial Officer, Alex Shvartsburg, reported the vesting of various equity awards and new grants of restricted and performance stock units on March 30, 2026.

LivaNova CEO Vladimir Makatsaria reported significant equity transactions, including RSU settlements, tax-related share dispositions, and new RSU and PSU grants.

LivaNova PLC's President of Global Epilepsy, Stephanie Bolton, reported the vesting of equity awards and new grants of restricted and performance stock units.

LivaNova's Chief Human Resources Officer, Natalia Kozmina, reported the vesting of restricted stock units, subsequent tax-related share disposals, and new grants of restricted and performance stock units.

LivaNova PLC's President of Cardiopulmonary, Franco Poletti, exercised stock appreciation rights and adjusted his direct beneficial ownership of ordinary shares.

LivaNova PLC's President of Cardiopulmonary, Franco Poletti, reported the vesting of 967 restricted stock units and the subsequent withholding of 416 shares for tax purposes.

LivaNova PLC Director Susan M. Podlogar acquired 2,355 ordinary shares through RSU vesting, with 269 shares withheld for tax obligations.

LivaNova PLC's Senior Vice President, Chief Legal Officer, and Company Secretary, Michael Damon Hutchinson, reported the vesting of restricted stock units and the subsequent sale of shares to cover tax liabilities.

LivaNova PLC Director Brooke Story reported the sale of 250 ordinary shares at $53.94 per share, reducing her beneficial ownership to 6,232 shares, executed under a 10b5-1 plan.

LivaNova PLC Director Donald Zurbay received a grant of 2,560 Restricted Stock Units under the company's 2025 Director Incentive Award Plan.

LivaNova PLC's President of Cardiopulmonary, Franco Poletti, settled 643 restricted stock units, leading to a net adjustment in his ordinary share holdings.